Oslo - Delayed Quote NOK

BerGenBio ASA (BGBIO.OL)

8.35

-0.31

(-3.61%)

At close: December 20 at 4:25:21 PM GMT+1

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today the appointment of Olav Hellebø as CEO. Mr. Hellebø will assume the position on November 21, 2024.

PR Newswire last month

BRRGF
BerGenBio Third Quarter Results 2024

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended September 30, 2024, and provided a business update.

PR Newswire last month

BRRGF
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from the Phase 1b portion of the BGBC016 study in first-line (1L) Non-Small Cell Lung Cancer (NSCLC) patients.

PR Newswire 2 months ago

BRRGF
BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update.

PR Newswire 3 months ago

BRRGF
BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today a collaboration with Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, to advance the clinical development of BerGenBio's selective AXL inhibitor bemcentinib in first line (1L) Non-Small Cell Lung Cancer (NSCLC) patients with STK11 mutations (STK11m). BerGenBio's on-going BGBC

PR Newswire 4 months ago

BRRGF
BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the independent Data and Safety Monitoring Board (DSMB) for BerGenBio's Phase 1b/2a BGBC016 study confirmed acceptable safety at the highest dose tested in the Phase 1b. As a result, the DSMB also recommended that under the study protocol, no additional patients will be required for Phase 1b.

PR Newswire 4 months ago

BRRGF
BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development

BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update.

PR Newswire 6 months ago

BRRGF
BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company.

PR Newswire 6 months ago

BRRGF
BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m).

PR Newswire 8 months ago

BRRGF
BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Dr. Mirella Spalluto of the University of Southampton today presented "Investigating the effects of AXL inhibition during respiratory viral infections" during the 6th Forum on Respiratory Infections in Glasgow, Scotland.

PR Newswire 10 months ago

BRRGF

Performance Overview

Return	BGBIO.OL	OBX Total Return Index
YTD	-69.96%	+9.51%
1-Year	-68.25%	+9.84%
3-Year	-99.49%	+24.90%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BerGenBio ASA (BGBIO.OL)

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Third Quarter Results 2024

BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial

BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development

BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Performance Overview